Quantcast
Last updated on April 24, 2014 at 5:00 EDT

Latest Cyclophilin Stories

2013-03-25 04:22:24

LUND, Sweden, March 25, 2013 /PRNewswire/ -- NeuroVive, a leading mitochondrial medicine company, announces that its shares have been approved for listing on NASDAQ OMX Stockholm by the exchange's Listing Committee. The first day of trading on NASDAQ OMX Stockholm will be April 10th and the last day of trading on the Swedish trading platform AktieTorget will be April 9th. The stock will be traded under the same ticker symbol, NVP. No new shares will be issued in...

2013-03-18 08:27:51

LUND, Sweden, March 18, 2013 /PRNewswire/ -- NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company announces that Anna Malm Bernsten and Boel Flodgren have been elected to the Company's Board. Both have exceptional track records and leadership experience and are expected to make a significant contribution to NeuroVive. Anna Malm Bernsten has more than 25 years of international marketing and sales experience in the healthcare industry. She was until...

2013-03-11 08:26:46

LUND, Sweden, March 11, 2013 /PRNewswire/ -- NeuroVive, a leading mitochondrial medicine company, announces it has completed the acquisition of a portfolio of novel cyclophilin inhibitors, technology platform assets and related intellectual property rights from the UK biotech company Biotica Ltd. The acquisition of these assets is important strategically as it will allow NeuroVive to broaden and deepen its pipeline of novel mitochondrial medicines. No financial details of the...

2013-02-01 08:25:12

LUND, Sweden, February 1, 2013 /PRNewswire/ -- NeuroVive, a leading mitochondrial medicine company, is pleased to announce the appointment of Jan Nilsson as Chief Operating Officer (COO). Jan will oversee the day-to-day operations of the Company and support the planned commercialisation of CicloMulsion(R) and NeuroSTAT(R), NeuroVive's leading products for the treatment of acute cardiovascular and neurological conditions through mitochondrial protection. Jan has over 30...

2012-11-20 08:25:39

BEIJING and LUND, Sweden, November 20, 2012 /PRNewswire/ -- NeuroVive, the leading mitochondrial medicine company, today announces a collaboration agreement with Sihuan Pharmaceutical Holdings Group Ltd. for the development and commercialisation in China of NeuroVive's most clinically advanced products CicloMulsion(R) and NeuroSTAT(R). Sihuan Pharmaceutical is one of the largest domestic pharmaceutical companies in China and the market leader in the fast-growing Chinese...

2010-01-20 18:22:37

Researchers at the National Institutes of Health and other institutions have discovered the third in a sequence of genes that accounts for previously unexplained forms of osteogenesis imperfecta (OI), a genetic condition that weakens bones, results in frequent fractures and is sometimes fatal. The newly identified gene contains the information needed to make the protein Cyclophilin B. This protein is part of a complex of three proteins that modifies collagen, folding it into a precise...

2009-09-09 09:09:56

In 2004, Jeremy Luban and colleagues from the University of Geneva, Switzerland, reported that New World owl monkeys (Aotus genus) make a fusion protein "“ AoT5Cyp "“ that potently blocks HIV-1 infection. The human genome encodes the equivalent of the 2 components of AoT5Cyp (i.e., TRIM5 and cyclophilin A), but humans unfortunately do not make the T5Cyp fusion protein. In their new study in the Journal of Clinical Investigation, Luban et al. have engineered a human HIV-1 inhibitor...

2008-11-03 09:00:40

Drug discovery company SCYNEXIS, Inc. today announced that data from preclinical studies of the Company's lead product candidate for hepatitis C (HCV), SCY-635, will be presented in poster sessions at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held in San Francisco, October 31-November 4, 2008. SCY-635 represents a new mechanism of action for the treatment of HCV infection and is the first candidate in a novel new class of...